Thus, this ovarian cancer type might be an attractive target for UPF1 drug leads, under conditions in which patients have an UPF1 or UPF2 amplification that stimulates the UPF1-dependent NMD pathway. This evidence concerns the gene UPF1 and ovarian carcinoma.